Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Petros Pharmaceuticals ( (PTPI) ).
On January 1, 2026, Petros Pharmaceuticals’ board approved, effective January 2, 2026, the grant of a total of 7,250,000 restricted stock units (RSUs) to Chairman Joshua Silverman, directors Bruce Bernstein and Wayne Walker, and President and Chief Commercial Officer Fady Boctor, with Silverman receiving 4,375,000 RSUs, Bernstein 1,875,000 RSUs, and Boctor and Walker 500,000 RSUs each. Half of each award vested immediately on the grant date, with the remaining half scheduled to vest six months later contingent on continued service, and the RSUs, which convert into common stock on a one-for-one basis, were granted outside the company’s existing 2020 Omnibus Incentive Compensation Plan under a separate Restricted Stock Unit Agreement, signaling a targeted equity-based incentive move for Petros’s leadership.
More about Petros Pharmaceuticals
Petros Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing prescription and over-the-counter therapeutics, with a particular emphasis on men’s health products.
Average Trading Volume: 246,231
Technical Sentiment Signal: Sell
Current Market Cap: $336.9K
For detailed information about PTPI stock, go to TipRanks’ Stock Analysis page.